MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
MacroGenics, Inc. (MGNX)
Last macrogenics, inc. earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.macrogenics.com
Company Research
Source: GlobeNewswire
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed ADC (MGC028) Investigational New Drug (IND) application submitted to FDA Conference call scheduled for today at?4:30 p.m. ET? ROCKVILLE, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended September 30, 2024. “The pending MARGENZA transaction as well as the recently received milestone payment from Incyte further solidify our financial position, enabling us to remain focused on advancing our pipeline of innovative product candidates. In that regard, we are pleased to have submitted the IND fo
Show less
Read more
Impact Snapshot
Event Time:
MGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGNX alerts
High impacting MacroGenics, Inc. news events
Weekly update
A roundup of the hottest topics
MGNX
News
- MacroGenics, Inc. (NASDAQ: MGNX) was upgraded by analysts at StockNews.com from a "sell" rating to a "buy" rating.MarketBeat
- MacroGenics, Inc. (NASDAQ: MGNX) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating.MarketBeat
- MacroGenics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- MacroGenics to Participate in Upcoming Investor ConferencesGlobeNewswire
- MacroGenics, Inc. (NASDAQ: MGNX) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
MGNX
Earnings
- 11/5/24 - Beat
MGNX
Sec Filings
- 11/8/24 - Form SC
- 11/5/24 - Form 8-K
- 11/5/24 - Form 10-Q
- MGNX's page on the SEC website